Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APR NYSE:BVS NYSE:CCV NASDAQ:IKNA NYSE:TBA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPRApria$37.50$37.45$22.36▼$40.00$1.34BN/A682,285 shsN/ABVSBioventus$6.97-5.7%$6.70$6.02▼$14.38$572.54M0.84428,839 shs402,711 shsCCVChurchill Capital Corp V$10.40$10.39$9.90▼$11.00$283.58MN/A167,770 shs23,136 shsIKNAIkena Oncology$1.38-0.7%$1.27$0.97▼$1.94$67.08M0.5114,988 shs40,273 shsTBAThoma Bravo Advantage$9.61$9.72▼$13.19$1.04BN/A1.40 million shs1.83 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPRApria0.00%0.00%0.00%0.00%0.00%BVSBioventus-5.68%-2.44%+3.87%-6.82%+18.34%CCVChurchill Capital Corp V0.00%0.00%0.00%0.00%0.00%IKNAIkena Oncology-0.72%+3.76%-1.43%+25.45%-14.81%TBAThoma Bravo Advantage0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPRApriaN/AN/AN/AN/AN/AN/AN/AN/ABVSBioventus2.984 of 5 stars3.40.00.00.01.83.31.3CCVChurchill Capital Corp VN/AN/AN/AN/AN/AN/AN/AN/AIKNAIkena Oncology2.7779 of 5 stars3.33.00.00.02.21.71.3TBAThoma Bravo AdvantageN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPRApria 0.00N/AN/AN/ABVSBioventus 2.75Moderate Buy$13.7597.27% UpsideCCVChurchill Capital Corp V 0.00N/AN/AN/AIKNAIkena Oncology 2.50Moderate Buy$3.00117.39% UpsideTBAThoma Bravo Advantage 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BVS, IKNA, TBA, APR, and CCV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPRApria$1.15B1.17$5.27 per share7.12$1.12 per share33.48BVSBioventus$567.70M1.01$0.55 per share12.58$2.80 per share2.49CCVChurchill Capital Corp VN/AN/A$1.94 per share5.36($1.68) per shareN/AIKNAIkena Oncology$9.16M7.27N/AN/A$2.61 per share0.53TBAThoma Bravo AdvantageN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPRApria$64.88MN/A0.0020.49N/A5.66%586.18%9.23%N/ABVSBioventus-$156.23M-$0.48N/A15.15N/A-7.11%15.61%4.01%N/ACCVChurchill Capital Corp V$24.09MN/A0.00∞N/AN/A-30.29%2.28%N/AIKNAIkena Oncology-$49.23M-$0.86N/AN/AN/AN/A-30.59%-27.55%8/14/2025 (Estimated)TBAThoma Bravo Advantage-$30KN/A0.00N/AN/AN/AN/AN/AN/ALatest BVS, IKNA, TBA, APR, and CCV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025IKNAIkena Oncology-$0.21-$0.18+$0.03-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPRApriaN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/ACCVChurchill Capital Corp VN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/ATBAThoma Bravo AdvantageN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPRApria8.581.091.06BVSBioventus1.851.410.99CCVChurchill Capital Corp VN/A0.070.07IKNAIkena OncologyN/A13.3113.31TBAThoma Bravo AdvantageN/A1.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPRApriaN/ABVSBioventus62.94%CCVChurchill Capital Corp V52.51%IKNAIkena Oncology75.00%TBAThoma Bravo AdvantageN/AInsider OwnershipCompanyInsider OwnershipAPRApriaN/ABVSBioventus33.00%CCVChurchill Capital Corp V20.00%IKNAIkena Oncology5.94%TBAThoma Bravo AdvantageN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPRApria6,08035.65 millionN/ANot OptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableCCVChurchill Capital Corp V227.28 million21.82 millionNot OptionableIKNAIkena Oncology7048.26 million45.39 millionNot OptionableTBAThoma Bravo AdvantageN/A102.40 millionN/ANot OptionableBVS, IKNA, TBA, APR, and CCV HeadlinesRecent News About These CompaniesMeta Invests Big in Startup Scale AI, Brings On Its CEO for AI Development EffortsJune 13, 2025 | investopedia.comThoma Bravo Advantage - Class ASeptember 25, 2024 | thestreet.comThoma Bravo plans to raise $20 billion for Thoma Bravo Fund XVIApril 10, 2024 | akm.ruAHg hires Thoma Bravo partner for North America pushJuly 26, 2023 | penews.comPThoma Bravo snaps up digital forensic software firm Magnet Forensics for $1.3BJanuary 23, 2023 | siliconangle.comSNCR Stock Falls After Thoma Bravo Buyout Falls ThroughJanuary 4, 2023 | thestreet.comSenate Democrats Scrutinize Rental-Pricing Software From Thoma Bravo UnitNovember 24, 2022 | msn.comThoma Bravo Makes Strategic Investment in Intel 471September 8, 2021 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeThe Apple Comeback Will Be Better Than the SetbackBy Gabriel Osorio-Mazilli | July 4, 2025View The Apple Comeback Will Be Better Than the SetbackSpotify's Massive Rally: Can New Features Sustain the Momentum?By Nathan Reiff | June 27, 2025View Spotify's Massive Rally: Can New Features Sustain the Momentum?BVS, IKNA, TBA, APR, and CCV Company DescriptionsApria NYSE:APRApria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.Bioventus NYSE:BVS$6.97 -0.42 (-5.68%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.96 0.00 (-0.07%) As of 07/11/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Churchill Capital Corp V NYSE:CCVChurchill Capital Corp V does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as One Judith Acquisition Corp. Churchill Capital Corp V was incorporated in 2020 and is based in New York, New York.Ikena Oncology NASDAQ:IKNA$1.38 -0.01 (-0.72%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 07/11/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Thoma Bravo Advantage NYSE:TBAThoma Bravo Advantage does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
